Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate CancerMatti Annala, Alexander W. Wyatt, Alan So et al.|European Urology|2017Cited by 218
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Alexander W. Wyatt, Werner J. Struss et al.|European Urology|2019Cited by 183
Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.Werner J. Struss, Alexander W. Wyatt, Matti Annala et al.|Journal of Clinical Oncology|2017Cited by 3
Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.Steven Yip, Kim N., Daniel Khalaf et al.|Journal of Clinical Oncology|2018Cited by 3